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Angiosarcoma — a malignant neoplasm 
secondary to radiotherapy for breast 
cancer in a female patient following 
breast-conserving treatment — a case 
report
ABSTRACT
Angiosarcoma is a rare malignant neoplasm, accounting for 1–2% of all sarcomas. The main cause of develop-
ing secondary angiosarcoma is radiotherapy. We analysed the case of a 52-year-old woman with breast cancer, 
who had undergone breast-conserving therapy. Four years after finishing treatment, she was diagnosed with 
secondary angiosarcoma in the irradiated area. The patient underwent a mastectomy. The disease relapsed six 
months after the operation in form of local recurrence, as well as liver and lung metastases. The patient’s condition 
gradually deteriorated despite treatment (chemotherapy and symptomatic management). The patient died due 
to cardiorespiratory failure nine months after the diagnosis of secondary malignancy.
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Introduction
The incidence of sarcomas in Poland is estimated 
at 2/100,000 per year; 1–2% of them are angiosarcomas 
(AS) [1, 2], which are soft tissue sarcomas stemming 
from the endothelial cells of blood or lymphatic vessels 
[3]. The most common locations of this tumour are the 
head, breast, and the limbs [4]. These neoplasms may 
occur as primary tumours, with no influence of external 
factors, or as secondary tumours — usually following 
radiotherapy (RT). The latter constitute about 0.5–5% 
of all sarcomas [5, 6]. Although the secondary AS of the 
breast is very rare and constitutes about 0.9 per 1000 cas-
es of malignant neoplasms of the breast, they are an 
important clinical issue because they are characterised 
by a poor prognosis. It is estimated that their number 
will grow due to the higher incidence of breast cancer 
and the use of RT in breast-conserving treatment [7–9].
Below, we present the case of a 52-year-old female 
breast cancer patient who had previously undergone 
breast-conserving therapy with a radical goal. Four years 
after finishing the above treatment, an AS with a high 
grade of malignancy was diagnosed in the RT area.
Case report
A 47-year-old woman came in for mammography 
(MMG) in November 2012, which showed a lesion of 
increased density with malignant characteristics (BI-
RADS 5), about 19 mm in size, in the upper exterior 
quadrant of the left breast, within 2 cm of the areola. 
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Figure 1. Pathology images of right breast tumour A. G2 Duct carcinoma (black arrow) and a lesion of non-invasive duct 
carcinoma (white arrow) (4× magnification). B. Angiosarcoma with a high malignancy level — pathological vascular fissures 
(white arrow) lined with abnormal neoplastic cells (black arrow) (20× magnification)
A B
In an ultrasonographically (USG) controlled fine-needle 
biopsy of the above-mentioned lesion, the presence of 
malignant cells was confirmed. In the same month, the 
patient underwent breast-conserving surgery (excision 
of the upper external quadrant along with the sentinel 
lymph node). In a surgical pathology test, metastases 
to the sentinel lymph node were detected, and a deci-
sion was made to excise the remaining axillary lymph 
nodes. The lesion was excised completely — macro-
scopically as well as microscopically. In a post-operative 
pathology examination, the presence of invasive grade 2 
(G2) ductal carcinoma (Figure 1A) was detected, with 
estrogen receptor (ER) expression in 80% of the tumour 
cells, and progesterone receptor (PR) expression in 
90% of the cells, but no human epidermal growth factor 
receptor 2 (HER2) expression was found and Ki-67 cell 
proliferation marker was present in 5% of the tumour 
cells. Distally, focal lesions of ductal carcinoma in situ 
(DCIS) were present. Metastases to one of the eight 
excised lymph nodes were detected. The clinical stage 
of the disease was marked as pT2N1M0.
The patient received four cycles of adjuvant chemo-
therapy (AC regimen — doxorubicin and cyclophos-
phamide) from January 2013 until March 2013, with 
subsequent adjuvant hormonal therapy with tamoxifen 
at a daily dose of 20 mg (beginning in March 2013). 
From April 2013 until June 2013, the patient was treat-
ed with postoperative radiotherapy for the area of the 
right breast, in radiation conditions of × 4MV, × 6MV 
up to a total dose of 50 Gy/2 Gy/in 25 fractions. For 
the post-operative area, the total dose was raised to 
66 Gy/2 Gy/in 33 fractions. During radiotherapy, an 
acute cutaneous post-radiation reaction occurred with 
a G2 intensity in the RTOG scale, which healed after 
a month’s time. 
In August of 2013, after the acute reaction had 
healed, redness and swelling of the skin of the right 
breast appeared again, and remained throughout the 
time during which routine examinations were conducted. 
On imaging — MMG and USG — performed outside 
of our hospital, no evidence of recurrent disease was 
detected. In July 2017, four years after completing 
radiotherapy, a cyanotic lesion on the skin of the right 
breast appeared, along with a small ulceration in the 
proximity of the nipple. Antibiotics and anti-coagulants 
were prescribed. Due to the continuing presence of the 
above-mentioned lesions, in December of 2017 sam-
ples were taken from the ulcerated lesion near the 
nipple (Figure 2A). Pathology examination revealed 
AS — a malignant neoplasm secondary to radiotherapy 
(Figure 1B). Computed tomography (CT) scans showed 
no evidence of distal metastases. The patient underwent 
mastectomy in January 2018. In July 2018, on imaging 
done outside of our hospital, metastases to the lungs and 
liver were shown. On examination upon hospital admis-
sion, traits of local recurrence were observed in the form 
of lumps in the scar from the right-side mastectomy. In 
August 2018, half a year after the surgery, the patient 
underwent palliative chemotherapy (ADIC regimen 
— doxorubicin and dacarbazine). After the first cycle of 
this treatment, laboratory testing showed anaemia and 
G3 neutropaenia. Treatment with granulocyte growth 
factor was applied, along with symptomatic treatment, 
and the patient’s condition improved. Within the same 
month, due to increasing dyspnea and recurring fluid in 
the pleural cavity (after draining the right pleural cavity 
twice), and clinical recurrence, a control CT scan was 
performed. The test showed local recurrence, metastases 
to the lungs and liver, a significant amount of fluid in the 
pleural cavity, and fungal lesions in the lungs (Figure 2B, 
C, D). In order to lessen the symptoms, talc pleurodesis 
was performed. In September 2018, in an angio-CT scan 
of the thorax, a sub-segmental pulmonary embolism was 
detected, along with progression of local infiltration and 
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Figure 2. Angiosarcoma in a 53-year-old female patient, 4 years after completion of radical treatment of breast cancer (breast-
conserving surgery, radiotherapy, chemotherapy). Computed tomography following contrast administration (venous phase). 
A. Tumour of right nipple-surrounding area (white arrow). Testing conducted previous to treatment (January 2018). B. Cystic 
metastases of angiosarcoma to the liver (white arrow), Testing conducted after chemotherapy (August 2018). C. Cystic 
metastases to the lungs (white arrow) and free flood in the pleural cavity (black arrow). Test conducted after chemotherapy 
(August 2018). D. Fungal cavities in the right lung (black arrow) — lung window. Testing conducted after chemotherapy 
(September 2018)
A B
C D
enlargement of fungal lesions in the lungs. The patient 
was given anti-fungal treatment and the best possible 
symptomatic treatment. Despite treatment, the patient’s 
state gradually worsened, and in September 2018 she 
died due to cardiorespiratory insufficiency.
Discussion
Angiosarcomas are very rare tumours, characterised 
by a high level of malignancy [10]. Factors predisposing 
towards the development of AS are: previous radiother-
apy, exposure to polyvinyl chloride, arsenic, and thorium 
dioxide, chronic swelling (described as Steward-Trewes 
syndrome in related literature), and probably exposure 
to UV radiation (especially cutaneous sarcomas of 
the head) [4, 10–16]. No co-occurrence with genetic 
syndromes has been proven, although 3% of patients 
with AS are diagnosed with Ollier’s disease, Maffuci 
disease, von Recklinghausen syndrome, retinoblastoma, 
or xeroderma pigmentosum [4, 13, 17–19].
In a retrospective study, Kirova YM et al. [20] 
showed that of 13,472 patients who underwent radio-
therapy due to early breast cancer, 35 developed sarco-
mas (48% — 12 patients had breast AS and 1 patient 
was found to have AS of thoracic region). The cumulated 
risk of RT-induced sarcoma has been calculated to be 
0.27% after 10 years, and 0.48% 15 years after treatment 
with radiation. The standardised incidence ratio (SIR) 
for sarcomas in patients with breast cancer, who previ-
ously underwent radiation therapy, has been calculated 
at 10.2; however, in women who did not receive RT, 
the SIR amounts to 1.3. Yap et al. [7] also observed an 
increase in sarcoma incidence in the area submitted 
to radiation. Among them, AS amounted to 56.8% of 
cases. However, in those who did not undergo RT, only 
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5.7% developed this malignancy. In a study by Huang et 
al. [21], an increased incidence of soft-tissue sarcomas 
was also confirmed (especially AS), in patients who had 
undergone RT due to breast cancer. The standardised 
incidence factor in the case of AS secondary to RT has 
been estimated at 26.2, and 2.1 in women who were not 
treated with RT.
It is thought that the highest incidence of radia-
tion-induced AS is in patients undergoing treatment 
for breast cancer of lymphoma [7, 21, 22]. The latency 
period from completion of RT to the development of 
breast AS varies from 3 to 25 years [15, 23–26]. The 
pathological mechanism of RT’s influence on the 
development of AS is not fully known yet. It suggests 
that radiation dosages above 50 Gy cause cellular 
apoptosis, and doses below 50 Gy cause DNA dam-
age and instability. Sarcomas often occur on the area 
surrounding the irradiated body part, where doses 
may vary [23, 24]. Attempts at modifying the radiation 
dosage, volume of the body space being irradiated, and 
the total RT time in breast cancer patients are being 
made in order to lower the risk of recurrent disease, 
as well as the occurrence of late-onset radiation com-
plications [27–29].
A primary breast AS usually occurs in women aged 
30–50 years as a lump of the breast, whereas the second-
ary AS usually develops in women aged over 60 years as 
a cutaneous lesion (a blue-cherry colour lump, swelling, 
erythematous patches) [15, 16, 26].
On imaging (USG, MMG), sarcomas of the breast 
give nonspecific symptoms — usually a thickening and 
swelling of the skin, similar to the lesions present in 
most women who undergo breast-conserving therapy 
and supplementary radiotherapy. This causes a delay 
in diagnosis and treatment. In the case of suspicion of 
a breast AS, the best imaging test is MRI [9, 30, 31]. 
The final diagnosis of AS is made based on the results 
of pathological testing [32, 33].
The tumours being discussed — besides a high rate 
of local recurrences — are characterised by a relatively 
high rate of distal metastases and are associated with 
poor prognosis. The most important prognostic factors 
related to poor outcomes are: the diameter of the tu-
mour, the depth of infiltration, positive surgical margins, 
the presence of metastases, or local recurrence after 
surgical resection [23, 34, 35]. The most common sites of 
distal metastases are the lungs [16, 36], but liver, cecum, 
tonsillar, cheek, oral cavity, and heart metastases are 
also documented. [37–40].
The only chance of cure in patients with secondary 
AS is when R0 margins are achieved during surgery [41, 
42]. In a case series of 14 patients observed for 12 years, 
a non-radical resection of the tumour was associated 
with rapid local recurrence and poor prognosis. The 
average survival time of patients who had undergone ex-
tensive surgery amounted to 42 months, when compared 
to six months in people who did not achieve R0 margins 
[24]. However, in a study by Seinen et al. [23], in 14 out 
of 24 patients who underwent a mastectomy, a surgical 
margin free of malignancy was achieved, when compared 
to two out of seven patients who underwent a tumour 
resection with a macroscopic margin equal to or greater 
than 2 cm. Only 3 women underwent an extensive re-
section of the area subjected to radiation, and in 2 of 
these patients the surgical margin was free of tumour 
cells. Despite achieving R0 margins in these patients, 
in about 2/3 of these patients local recurrence took 
place, and the median survival specific to the disease 
was 37 months.
In the case of AS, RT may be considered, although 
most radiation oncologists are not very willing to apply 
it to an area which was previously irradiated. Some 
authors claim that hyper-fractioned adjuvant RT after 
surgery may be a promising method of secondary AS 
treatment. [43–45].
So far, there has been a lack of unequivocal data 
regarding adjuvant chemotherapy in this indication [4, 
17, 46, 47]. The most effective agents are doxorubicin 
and ifosfamide [48]. Some studies have proven that si-
multaneous treatment with neoadjuvant chemotherapy 
and hyperthermia in patients with poor prognostic soft 
tissue sarcoma results in better survival [49].
Currently, the greatest hope in treating sarcoma 
patients is based on the molecular biology evolution. 
Bevacizumab, sorafenib, and pazopanib were studied 
among other agents [50, 51]. A varied response to 
treatment with sorafenib and bevacizumab was found 
[51–53]. In the case of pazopanib, an improvement 
in progression-free survival was found; however, the 
effectiveness of the drug may be limited due to the 
sarcoma’s acquisition of immunity to a given therapy 
[54, 55]. Anti-angiogenic treatment may play a role in 
some soft tissue therapy, which is why further research 
is necessary for the planning of effective therapeutic 
regimens [51, 52].
 In conclusion, malignant neoplasm secondary to RT 
— an AS with a high level of malignancy — developed 
just four years after irradiation. The disease course was 
aggresive — just a month after surgical resection due to 
AS, local recurrence appeared, along with metastases 
to the lungs and liver. The patient survived only nine 
months after receiving the diagnosis. Studies aimed 
at identifying factors that amplify the risk of acquiring 
AS secondarily to RT are needed. Awareness regard-
ing late-onset complications of RT, such as secondary 
neoplasms, should be raised among doctors who are 
responsible for patient observation, in order for the 
earliest possible detection to take place.
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